1. Boudewijn B, Vasbinder C, Nelemans PJ, Kessels GH, Kroon AA, de Leeuw PW, van Engleshoven JMA. Diagnostic test for renal artery stenosis in patients suspected of having renovascular hypertension: A meta-analysis. Ann Intern Med 2001; 135:401-411.

2. Weinberg MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med. 1993; 153:2125-2129.

3. Young WF. Primary aldosteronism: management issues. NY Acad Sci 2002; 970:61-76.

4. Ross E, Regolisti G, Negro A, Sani C, Davoli S, Preazoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15:896-9025.

5. Racine MC, Douville P, Lebel M. Functional tests for primary aldosteronism: value of captopril suppression. Curr Hypertens Rep. 2002; 4:245-249.

6. Castro Ol, Yu X, Kem DC. Diagnostic value of the post-captopril test in primary aldosteronism. Hypertension. 2002; 39:935-938.

7. Bravo EL, Tarazi RC, Dustan HP, et al. The changing clinical spectrum of primary aldosteronism. Am J Med 1993; 74:641-651.

8. Young WF Jr. Primary aldosteronism: update on diagnosis and treatment. Endocrinologist 1997; 7:213-221.

9. Ganguly A. Primary Aldosteronism. New England Journal of Medicine 1998; 1828-1834.

9a.- Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallin M, Feltrin GP, Pessina AC. Identification of the etiology of primary aldosteronism with adrenal vein sqmpling in  patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab  2001: 86: 1083-90.

9. Falli F, Sonino N, Armanini D, Luzzi T, Pedini F, Pasini C, Mantero F. A new family with dexamethasone-suppressible hyperaldosteronism: aldosterone unresponsiveness to angiotensin II. Clin Endocrimol 1988; 29:297-308.

10. Ganguly A, Crim CE, Weinberger MH. Anomalous postural aldosterone response in glucocorticoid-suppressible hyper-aldosteronism. New Engl J Med 1981; 305:991-993.

11. Stowasser M, Gordon RD. Familial hyperaldosteronism. J Steroid Biochem & Mole Biol. 2001; 78:215-229.

12. Ulick S, Chu MD. Hypersecretion of a new corticosteroid, 18-hydroxycortisol in two types of adrenocortical hypertension. Clin Exp Hypertens 1982; A4: 1771-1777.

13. Ulick S, Chu MD, Land M. Biosynthesis of 18-oxocortisol by aldosterone-producing adrenal tissue. J Biol Chem 1983; 258:5498-5502.

14. Litchfield WR, New MI, Coolidge C, Lifton RP, Dluhy RG. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediabel aldosteronism. J Clin Endocrine and Metabolism 1997; 82:3570-3572.

15. Grim CE, Weinberger MH. Familial, dexamethasone-suppressible, normokalemic hyperaldosteronism. Pediatrics 1980; 65:597.604

16. Connell JMC, Kenyon CJ, Corrie JET, Fraser R, Watt R, Lever AF. Dexamethasone-suppressible hyperaldosteronism: adrenal transitional cell hyperplasia? Hypertension 1986; 8:669-676.

17. New MI, Peterson RE, Saenger P, Levine LS. Evidence for an unidentified ACTH-induced steroid hormone causing hypertension. J Clin Endocrinol Metab 1976; 43:1283-1293.

18. Stowasser M, Gordon RD. Primary aldosteronism: learning from the study of familial varieties. J Hypertens 2000; 18:1165-1176.

19. Litchfield WR, New MI, Coolidge C, Lifton RP, Dluhy RG. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997; 82:3570-3573.

20. Stowasser M, Gartside MG, Gordon RD. A PCR-based method of screening individuals of all ages, from neonates to the elderly, for Familial Hyperaldosteronism Type 1. Aust NZ J Med 1997; 27:685-690.

21. Jamieson A, Inglis GC, Campbell M, Fraser R, Connell JMC. Rapid diagnosis of glucocorticoid suppressible hyperaldosteronism in infants and adolescents. Arch Dis Child 1994; 71:40-43.

22. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11ß-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355:262-265.

23. Bertani-Dziedzic LM, Krstulovic AM, Dziedzic SW, et al. Analysis of urinary metanephrines by reversed-phase high-performance liquid chromatography and electrochemical detection. Clin Chim Acta 1981; 110:1-8

24. Kushnir MM, Urry FM, Frank EL, Roberts WL, Shushan B. Analysis of catecholamines in urine by positive-lon electrospray tandem mass spectrometry. Clinical Chemistry 2002; 48:323-331.

25. Taylor RL, Singh RJ. Validation of liquid chromatography-tandem mass spectrometry method for analysis of urinary conjugated metanephrine and normetanephrine for screening of pheochromocytoma. Clinical Chemistry 2002; 48:533-539.

26. Eisenhofer G, Keiser H, Priberg P, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 1998; 83:533-522.

27. Lenders JWM, Pacak K, Eisenhofer G. New advances in biochemical diagnosis of pheochromocytoma. NY Acad Sci 2002; 970:29-40.

28. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287:1427-1434.

29. Sebel E, Hull R, Kleerekoper M, Stokes G. Responses to glucagon in hypertensive patents with and without a pheochromocytoma. Am. J Med Sci. 1974; 267:337-343.

30. Bravo E, Tarazi R, Fouad F, Vidt D, Gilford R. Clonidine suppression test. A useful aid in the diagnosis of pheochromocytoma. N Engl J Med. 1981; 305:623-626.

31. Sjoberg RJ, Simcic KJ, Kid GC. The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. Arch Intern Med 1992; 152:1193-1197.

32. New MI. Hypertension in congenital adrenal hyperplasia and apparent mineralocorticoid excess. NY Acad Sci 2002; 970:145-154.